NYSE: DHR · Industrial Applications and Services · 7 alerts · CIK 313616
Share price
$229.91Close, Nov 16
Market cap
$162B
Shares outstanding
703.53MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Industrial Instruments For Measurement, Display, and ControlSIC 3823
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Danaher Corp filings on SEC EDGAR ↗
Danaher EVP Gregory M. Milosevich Sells $484K of Stock
Gregory M. Milosevich, EVP, sold 2,100 shares of Danaher Corp at $230.62 a share, worth $484K in total on Nov 9, 2026. Shares held after the trade: 22,367 (-8.6%).
Matthew McGrew, EVP, sold 17,385 shares of Danaher Corp at $235.69 a share, worth $4.1M in total on Nov 9, 2026. Shares held after the trade: 12,674 (-57.8%).
Danaher VP, CAO Christopher Bouda Sells $1.78M of Stock
Christopher Bouda, VP, CAO, sold 7,598 shares of Danaher Corp at $234.54 to $234.58 a share (average $234.56) in 2 transactions, worth $1.78M in total on Oct 28, 2026. Shares held after the trade: 9,107 (-26.3%).
Matthew McGrew, EVP, sold 29,754 shares of Danaher Corp at $235.35 to $236.09 a share (average $235.74) in 2 transactions, worth $7.01M in total on Oct 28, 2026. Shares held after the trade: 12,674 (-55.2%).
Danaher reported third quarter 2026 revenues of $6.6 billion, an 8.5% increase year-over-year, with net earnings rising 34.5% to $1.2 billion. The company raised its full-year 2026 adjusted diluted net earnings per share guidance to a range of $8.57 to $8.62, citing improving trends across end markets.
Term
Q3 2026
“We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance.”
Julie Sawyer Montgomery, President and Chief Executive Officer
“Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world.”
Julie Sawyer Montgomery, President and Chief Executive Officer
Danaher Corporation reported a significant increase in net earnings from continuing operations to $3.1 billion for the nine months ended September 25, 2026, compared to $2.4 billion in the prior year. The company executed substantial acquisition activity, spending $9.9 billion on cash acquisitions, which contributed to a notable increase in goodwill and intangible assets on the balance sheet.
Danaher Corporation increased its Board of Directors to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg as new directors, effective October 9, 2026. Mr. Comas is the company's former CFO, and Dr. Hershberg is the former CEO of HilleVax, Inc. Both will serve until the next annual meeting and participate in the standard non-employee director compensation program.